**Supplementary Methods**

“Overcoming MET-dependent Resistance to Selective RET Inhibition in Patients with RET Fusion–positive Lung Cancer by Combining Selpercatinib with Crizotinib”

doi: 10.1158/1078-0432.CCR-20-2278

**NGS platforms and MET detection assays**

Three different platforms were utilized for solid tumor NGS at each institution. MSKCC (New York, NY): briefly, normalized coverage values for each exon in the panel from the tumor are divided by normalized coverage values from a sample type matched normal [i.e., formalin-fixed, paraffin-embedded (FFPE) normal for FFPE tumor]. Logarithmic fold change values are used for segmentation and parametrizing a null background model from which P values are generated. Genes which fall onto segments with fold change ≥ 2 and P < 0.05 are reported as amplifications (1). Dana- Farber Cancer Institute (Boston, MA): RobustCNV performs a robust linear regression against the panel of normal samples to calculate copy ratios. Circular binary segmentation is again used to segment the data, and event identification is performed on the basis of the observed variance of the data points. Estimated copy number was calculated using the following published formula: CR = (TC/2) × P + (2/2)(1 - P), where CR is the median copy ratio for all intervals in a gene, TC is the number of copies in the tumor sample, and P is purity (2, 3). Sarah Cannon Cancer Center (Nashville, TN): The Foundation One platform was used for solid tumor NGS and MET detection (4).

**HBEC-RET cell lines**

LC-2/ad cells were obtained from Riken Bioresource Center (Japan). The HBEC-RET cell line expressing a *CCDC6/RET* fusion cDNA was generated as described previously (5). HBEC-RET cells were infected with retroviruses generated from empty pMSCV-PIG retroviral vector (HBEC-RET-EV) or pMSCV-PIG vector containing a *MET* cDNA (HBEC-RET+MET).

**Cell viability assays**

Cells were plated directly into selpercatinib and grown for 96 hours, and AlamarBlue was added during the last 6 hours and quantified using a fluorescence plate reader (Ex 530 nm, Em 585 nm). All conditions were tested in triplicate, and nonlinear regression was used to plot growth curves and estimate IC50 values.

**PCR**

CCDC6-RET was detected by RT-PCR using CCDC6 exon 1 forward (5’-ATGGCGGACAGCGCCAGCGAGA-3’) RET exon 12 reverse (5’-CTTTCAGCATCTTCACGGCCA-3’) primers. Amplified products were separated by gel electrophoresis, and quantitative PCR to detect MET utilized a Taqman *MET* gene expression assay kit (Hs04329783).

**Patient-derived organoids**

A pleural effusion specimen was obtained from the patient described in Case 1. After red blood cell lysis and CD45 depletion, the remaining cells resuspended in Matrigel (Corning) and were allowed to solidify and organoids were usable after passage 3 in Renaissance Essential Tumor Medium (Cellaria) supplemented with B-27 (Thermo Fisher Scientiﬁc).

**FISH of MET ampliﬁcation**

FISH analysis was performed on parafﬁn-embedded organoids. Two-color probes against MET (MET-20-OR) and Centromere 7 (CHR07–10-GR) were purchased from Empire Genomics. Baked slides were prepared, antigen retrieval performed, and treated with 0.004% pepsin in 0.01 N hydrogen chloride. Slide denaturation with probe mixture that was followed by overnight hybridization, which were then washed, dehydrated, and mounted.

**Cell growth assay**

TrypLE Express (Invitrogen) was applied to the cultured organoids to dissociate them into single cells and seeded on ultralow attachment microplates (Corning). After overnight incubation, cells were treated with DMSO, selpercatinib (Chemgood), crizotinib (Thermo Fisher Scientiﬁc), or with combination, with representative images of organoids captured after 6 days. CellTiter-Glo 3D (Promega) was used to measure cell viability. Statistical signiﬁcance was assessed using a two- tailed *t* test.

**Western blots and antibodies**

The dissociated organoids were treated with drug overnight, lysed with RIPA buffer (Boston BioProducts) and protease and phosphatase inhibitor cocktails (Sigma- Aldrich). BCA assay (Pierce) was performed for equivalent protein concentration of each sample. Denatured samples were immuno- blotted using anti-phospho-MET (Tyr1234/1235; #3126), anti-phos- pho-RET (Tyr905; #3221), anti-MET (#8198), anti-RET (#3223), Akt (#9272), pS473 Akt (#4060), ERK1/2 (#9102), pT202/Y204 ERK1/2 (#4370), all purchased from Cell Signaling Technology, and anti- HSP90 (#sc-7947) purchased from Santa Cruz Biotechnology. All Western blots shown were run using the same protein lysate, but AKT, pAKT, ERK, and pERK were blotted together, and the HSP90 loading control shown is from that set of blots.

**SPPs of selpercatinib and crizotinib**

Each SPP was sponsored by LOXO and drafted in collaboration between LOXO and the site primary investigator. Each protocol enrolled a single patient after review by the FDA and approval by the site IRB.

**References**

1. Ross DS, Zehir A, Cheng DT, Benayed R, Nafa K, Hechtman JF, et al. Next- generation assessment of human growth factor receptor 2 (ERBB2) ampli- ﬁcation status: clinical validation in the context of a hybrid capture-based, comprehensive solid tumor genomic proﬁling assay. J Mol Diagn 2017;19: 244–54.
2. Bi WL, Greenwald NF, Ramkissoon SH, Abedalthagaﬁ M, Coy SM, Ligon KL, et al. Clinical identiﬁcation of oncogenic drivers and copy-number alterations in pituitary tumors. Endocrinology 2017;158:2284–91.
3. Carter SL, Cibulskis K, Helman E, McKenna A, Shen H, Zack T, et al. Absolute quantiﬁcation of somatic DNA alterations in human cancer. Nat Biotechnol 2012;30:413–21.
4. Schrock AB, Frampton GM, Suh J, Chalmers ZR, Rosenzweig M, Erlich RL, et al. Characterization of 298 patients with lung cancer harboring MET Exon 14 skipping alterations. J Thorac Oncol 2016;11:1493–502.
5. Li GG, Somwar R, Joseph J, Smith RS, Hayashi T, Martin L, et al. Antitumor activity of RXDX-105 in multiple cancer types with RET rearrangements or mutations. Clin Cancer Res 2017;23:2981–90.